Research and Clinical Trials

Brief Description  
  • The primary objective of this study is to determine the progression-free survival (PFS) from enrollment for patients with non-bulky stage I and II Hodgkin Lymphoma.
  • The secondary objective is to evaluate the complete response (CR) rate of patients diagnosed with non-bulky stage I and II Hodgkin lymphoma following PET response-adapted chemotherapy with or without radiation therapy.
  • All patients begin treatment with 2 cycl
Who may be Eligible  
  • Histologically documented Hodgkin Lymphoma sub classified according to the WHO modification of the Rye Classification. Staged according to the Modified Ann Arbor Staging Classification system. Patients must have clinical stage IA, IB, IIA, or IIB. Patients with “E” extensions will be eligible if all other criteria have been met. Nodular lymphocyte predominant Hodgkin lymphoma is excluded.
  • Patients may not have a mediastinal mass >0.33 maximum intrathoracic diameter or peripheral or retroperitoneal adenopathy >10 cm in its largest diameter.
  • No prior treatment (chemo or radiation therapy for Hodgkin lymphoma.
  • Measurable disease must be present either on physical examination or imaging studies.
  • No “currently active” second malignancy other than non-melanoma skin cancers.
  • Age 18-60 with Performance status 0-2
  • LVEF by Echo or MUGA WNL
  • DLCO >/= 60% by Pulmonary Function Test. Without symptomatic pulmonary disease.
  • Adequate renal and liver function and adequate neutrophil and platelet counts (correlative lab data required)
IRB Number  
Principal Investigator  
Miller, David

For More Information, Contact  Sandra  , Mizzi
Phone:  (704) 355-7430  Fax:  (704) 355-1188  
Address:1025 Morehead Medical Drive Suite 600 Charlotte, NC 28204